RxDoctor Payments Data

Stephen Caldwell

Gastroenterology · Charlottesville, VANPI 1396814919

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,499 of the $1,953 with a category attached, or 76.8%. Kowa Research Institute, Inc. accounts for 97.2% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in VA, where the typical reported total is $3,407.

$1,953in general payments, 2019–2025

Across 4 payments — averaging $488.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Research Institute, Inc.$2K
  • Siemens Medical Solutions USA, Inc.$49
  • Echosens North America, Inc.$6
$1,821,624in research payments, 2019–2025

Across 322 payments — averaging $5657.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$900K
  • E.r. Squibb & Sons, L.L.C.$509K
  • Madrigal Pharmaceuticals$203K
  • Ipsen Bioscience Inc.$71K
  • Ultragenyx Pharmaceutical Inc.$49K
  • Ipsen Pharma SAS$43K
  • plus $46K from 3 others

What the payments were for

  • Travel & lodging$1,49977%
  • Food & beverage$45423%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,953 in reported general payments places this provider in the 35th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$19,193
Medicare patients
115
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin31$105,005
Ursodiol87$10,934
Entecavir14$4,430
Lactulose27$1,374
Mycophenolate Mofetil11$1,022
Azathioprine26$703
Omeprazole14$427
Tenofovir Disoproxil Fumarate14$414
Spironolactone24$328
Pantoprazole Sodium14$324
Prednisone22$249
Carvedilol27$223
Furosemide14$56

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →